Edition:
United Kingdom

Camurus AB (CAMX.ST)

CAMX.ST on Stockholm Stock Exchange

75.30SEK
5:00pm BST
Change (% chg)

2.30kr (+3.15%)
Prev Close
73.00kr
Open
76.20kr
Day's High
76.60kr
Day's Low
74.60kr
Volume
41,491
Avg. Vol
61,783
52-wk High
111.51kr
52-wk Low
54.66kr

Latest Key Developments (Source: Significant Developments)

Camurus Partner Braeburn To File Action, Seeking To Overturn Market Exclusivity To Sublocade
Tuesday, 9 Apr 2019 

April 9 (Reuters) - Camurus AB ::CAMURUS - US PARTNER, BRAEBURN INC., ANNOUNCED WILL FILE ACTION IN FEDERAL DISTRICT COURT FOR DISTRICT OF COLUMBIA, SEEKING TO OVERTURN 3-YEAR MARKET EXCLUSIVITY GRANTED BY FDA TO SUBLOCADE.SEEKS IMMEDIATE MARKET APPROVAL OF BRIXADI™ IN US.CAMURUS - BRAEBURN INFORMED HAS SUBMITTED CITIZEN PETITION TO FDA, REQUESTING THAT IT REVOKES ORPHAN DRUG DESIGNATION FOR SUBLOCADE.  Full Article

Camurus' Rights Issue Oversubscribed
Wednesday, 27 Mar 2019 

March 27 (Reuters) - Camurus AB ::CAMURUS' RIGHTS ISSUE OVERSUBSCRIBED.VIA RIGHTS ISSUE CO WILL RECEIVE ABOUT SEK 403 MILLION BEFORE DEDUCTION OF TRANSACTION COSTS.  Full Article

Camurus: CHMP Recommends Approval Of Buvidal (Cam2038) For Treatment Of Opioid Dependence
Friday, 21 Sep 2018 

Sept 21 (Reuters) - Camurus AB ::CHMP RECOMMENDS APPROVAL OF BUVIDAL® (CAM2038) FOR TREATMENT OF OPIOID DEPENDENCE.FINAL DECISION BY EUROPEAN COMMISSION IS EXPECTED NOVEMBER 2018.  Full Article

Camurus: Positive Topline Results From Phase 1 Study
Thursday, 31 May 2018 

May 31 (Reuters) - CAMURUS AB ::CAMURUS ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 1 STUDY OF LONG-ACTING TREPROSTINIL FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION.TOLERABILITY OF CAM2043 WAS GENERALLY GOOD WITH NO OBSERVATIONS OF UNEXPECTED OR SERIOUS ADVERSE EVENTS.IS PREPARING FOR CONTINUED CLINICAL DEVELOPMENT OF CAM2043 FOR TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH).CONTINUED CLINICAL DEVELOPMENT OF CAM2043 TO BE INITIATED FOLLOWING PLANNED DISCUSSIONS WITH HEALTH-AUTHORITIES IN 2018.  Full Article

Camurus AB Q4 Net Revenue Sek 5.5 Million Versus Sek 37.1 Million Year Ago
Thursday, 15 Feb 2018 

Feb 15 (Reuters) - CAMURUS AB ::Q4 NET REVENUE SEK 5.5 MILLION VERSUS SEK 37.1 MILLION YEAR AGO.Q4 OPERATING LOSS SEK 66.1 MILLION VERSUS LOSS SEK 35.1 MILLION YEAR AGO.NO DIVIDEND IS PROPOSED FOR THE FINANCIAL YEAR 2017..  Full Article

Camurus Q4 Operating Loss Widens To SEK ‍66.1​ Million
Thursday, 15 Feb 2018 

Feb 15 (Reuters) - Camurus Ab ::Q4 NET SALES SEK ‍5.5​ MILLION VERSUS SEK 37.1 MILLION YEAR AGO.Q4 OPERATING LOSS SEK ‍66.1​ MILLION VERSUS LOSS SEK 35.1 MILLION YEAR AGO.  Full Article

Camurus Q3 operating loss widens to SEK ‍67.1​ million
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - CAMURUS AB :Q3 NET REVENUE SEK ‍12.5​ MILLION VERSUS SEK 30.5 MILLION YEAR AGO.Q3 OPERATING LOSS SEK ‍-67.1​ MILLION VERSUS LOSS SEK 16.6 MILLION YEAR AGO.  Full Article

Camurus says FDA grants priority review of NDA for weekly and monthly CAM2038 Buprenorphine depots
Monday, 18 Sep 2017 

Sept 18 (Reuters) - Camurus Ab :Camurus announces that FDA grants priority review of NDA for weekly and monthly CAM2038 buprenorphine depots for treatment of opioid use disorder.NDA for CAM2038 submitted on July 19 by Camurus' U.S. Partner Braeburn, comprises data from seven clinical trials, including two phase 3 trials.  Full Article

Camurus and Braeburn announce submission of NDA for long-acting buprenorphine (CAM2038) for opioid use disorder
Thursday, 20 Jul 2017 

July 20 (Reuters) - CAMURUS AB ::CAMURUS AND BRAEBURN ANNOUNCE SUBMISSION OF NDA FOR LONG-ACTING BUPRENORPHINE (CAM2038) FOR OPIOID USE DISORDER.IF APPROVED, CAM2038 WOULD PROVIDE WEEKLY AND MONTHLY DOSING OPTIONS FOR PATIENTS WITH OPIOID USE DISORDER.PRIORITY REVIEW OF NDA HAS BEEN APPLIED FOR WHICH, IF GRANTED, WOULD SHORTEN REVIEW PROCESS OF CAM2038.  Full Article

Camurus Q2 operating loss widens to SEK ‍58.7​ mln
Thursday, 13 Jul 2017 

July 13 (Reuters) - CAMURUS AB ::Q2 REVENUE SEK ‍19.1​ MILLION VERSUS SEK 25.8 MILLION YEAR AGO.Q2 OPERATING LOSS SEK ‍58.7​ MILLION VERSUS LOSS SEK 25.9 MILLION YEAR AGO.  Full Article